Ofev Costs to Treat PF-ILD Should Be Reimbursed in Canada, Groups Say
People should be reimbursed for costs of using Ofev (nintedanib) to treat progressive fibrosing interstitial lung diseases (PF-ILD), two agencies that help to guide health policy in Canada — the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et services sociaux…